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observed FOXP3 protein expression exclusively in infiltrating lym-
phocytes,2,3 a recent article by Zuo et al4 reported the expression of
both FOXP3 protein and mRNA in human breast epithelial cells.
Their FOXP3 protein expression data, obtained using a polyclonal
antibody, are contrary to our findings with the anti-FOXP3 236A/E7
monoclonal antibody2,3 and studies are ongoing to investigate the
reasons for this discrepancy.However, using real-timePCRthis group
have demonstrated FOXP3mRNA expression in human andmurine
mammary epithelial cells.4 These data thus suggest that the quantifi-
cation of FOXP3 mRNA levels is not a surrogate marker for Tregs
within the breast tumor microenvironment. Moreover, as it is re-
ported that normal breast tissue has high epithelial FOXP3 mRNA
expression4 and low Treg numbers,2 while tumors have reduced epi-
thelial FOXP3mRNA expression4 and increased Treg numbers2 then
it is possible that these factorsmay cancel out and obscure any clinical
significance dependent onTreg-derived FOXP3 expression. Thismay
also have contributed to the lack of clinical significance provided by
this study of FOXP3mRNA expression in breast cancer patients.1
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Age Group–Specific Gap Between
Treatment Cost of and Mortality Due
to Breast and Colorectal Cancer
TOTHEEDITOR: Wereadwith great interest the articles bySanoff
et al1 andCrivellari et al2 on the treatment of older patientswithbreast
and colorectal cancer. Both articles review the special needs of elderly
population during cancer treatment.
In a country like Hungary, where health care resources aremore
limited, the efficiency and equity problems of health care are more
important.Weanalyzed theannual (2001),nationwide treatment cost
distribution of breast3 and colorectal4 cancer. We compared the an-
nual out- and inpatient care treatment cost of and the annual number
of deaths due to breast and colorectal cancer according to age groups.
Datawere extracted from the nationwide the database of theNational
Health Insurance Fund Administration (OEP), the only health care
financing agency inHungary, containing routinely collected financial
data. Compared with Medicare claims data, the Hungarian OEP’s
database covers the whole country and all age groups, not only those
older 65 years of age.5
We found that women age birth to 64 accounted for 42% of all
deaths due to breast cancer and they received 72% of the health
insurance expenditures for in- andoutpatient care treatment of breast
cancer. In contrast, women older than 65 accounted for 58% of all
deaths due to breast cancer and received only 28% of treatment cost.
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Fig 1. Distribution of annual number of
deaths and annual treatment cost of breast
and colorectal cancer according to age
groups (Hungary).
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In case of colorectal cancer, 26% of all deaths due to colorectal cancer
occurred in people from birth to 64 years, while they consumed 41%
to 43% of treatment cost. People older than 65 account for 74% of
deaths due to colorectal cancer and received only 57% to 59%of all of
the treatment cost (Fig 1).
Taking into consideration even the natural course of these dis-
eases, there is a shift between the distribution of treatment cost of and
deaths due to breast and colorectal cancer in favor of younger age
groups. Max et al reported a similar finding in cervical cancer, where
almost two thirds (64%) of the deaths due to cervical cancer occurred
among women younger than 65, while they represent 84.2% of hos-
pital costs. Most of these differences are derived from the different
preferences in treatment, and the undertreatment of senior patients
older than 65 years resulted in a higher breast cancer mortality.6 Our
studyalsoconfirmed thatolder colorectal cancerpatients are less likely
to receive treatment.7
Although the undertreatment of elderly population can be ex-
plainedpartlyby thegeneral health statusof seniorpeople, it is amajor
challenge for oncologists to balance the risks andbenefits of treatment
in elderly patients on an individual level. Health care financing agen-
cies face the same challenge in providing equal access to treatment for
elderly patients on a population level.
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IN REPLY: Dr Boncz and colleagues present an interesting over-
view of the age-related differential distribution of health care costs, a
surrogate for health care resource utilization, among Hungarian pa-
tients with breast and colorectal cancer. In a society that necessarily
caps spending on health care, how does one allocate that precious
resource? The preponderance of money spent on patients younger
than65 inHungary is certainly striking, particularly for youngwomen
with breast cancer who account for only 42% of Hungarian breast
cancer deaths yet receive 72% of the breast cancer health care expen-
ditures. This vastly unequal cost distribution suggests that olderHun-
garian patients may be undertreated for their cancers and do not get
their proportionate share of resources based on disease burden. These
findings are in linewithAmerican studies,wherehealth care resources
are assumed to be more plentiful, showing a marked decline in colo-
rectal cancer treatment with age.1
We thoroughly agree with Boncz et al’s assertion that individu-
alized care is the gold standard for treatment of elderly patients with
cancer.2 That is, in order to avoid undertreatment of the fit elderly or
overtreatment of the frail, treatment decisions in older patients must
be individualizedbasedonphysicianandpatientpreference, function,
and individual health rather than chronological age. This is particu-
larly true considering that there are clear data that colorectal cancer
patients 70 or older who were enrolled on clinical trials had equal
benefitwith similar toxicitywhen treatedwithoxaliplatin-containing3
and irinotecan-containing regimens4 as did younger patients. Both
younger andolder fit patientswith stage IV colorectal cancer are likely
tohave a similarmedian survival of 20monthswithoxaliplatin, folinic
acid, and fluorouracil (FOLFOX) compared with 12 to 14 months
with fluorouracil plus leucovorin or 6 months with best supportive
care. Devaluing this benefit for the older person by preferentially
directing resources to relatively youthful patients is problematic.
With individualized care as a gold standard, future attempts to
assess theprogressof cancer care in the elderlywill need to incorporate
novel quality measures beyond cost and use of recommended care—
both reasonable surrogates for aggressiveness of care, but poor mea-
sures of appropriate individualized care. Innovative quality measures
that encompass some aspects of care essential to individualized
decision making have already been used5,6 to assess the quality of
colorectal cancer care. Hopefully using similar measures adapted
to the needs of elderly cancer patients, wewill be better equipped to
study the success of our efforts to individualize the care of the
elderly with cancer.
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